Dr. William G. Kaelin Jr. Joins IQVIA's Board of Directors

On November 5, 2025, IQVIA Holdings Inc. (NYSE:IQV), a prominent player in the global healthcare landscape, announced a significant addition to its Board of Directors with the appointment of Dr. William G. Kaelin Jr. This strategic move is poised to enhance IQVIA's leadership in clinical research services and healthcare intelligence.

Dr. Kaelin is a distinguished Senior Physician-Scientist at Brigham and Women’s Hospital in Boston. He also serves as the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Notably, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine in 2019 for his pivotal research on oxygen sensing and the role of the von Hippel-Lindau (VHL) tumor suppressor protein. His scientific contributions extend beyond this accolade, as he has received numerous prestigious awards, including the Albert Lasker Basic Medical Research Award and the Wiley Prize in Biomedical Sciences from Rockefeller University.

In addition to his esteemed research career, Dr. Kaelin is currently a board member of Eli Lilly and Company, where he chairs the Science and Technology Committee. His extensive experience in oncology and biomedical innovation is expected to provide invaluable insights to IQVIA as the company continues to navigate the complexities of healthcare and clinical research.

Ari Bousbib, Chairman and CEO of IQVIA, expressed his excitement regarding Dr. Kaelin's appointment, stating, “I am very pleased to welcome Bill to our board of directors. Bill is a world-renowned scientist and physician with deep expertise in oncology and biomedical innovation and will be an outstanding addition to our board.” This welcoming sentiment underscores the confidence that IQVIA's leadership has in Dr. Kaelin's ability to contribute to the company's mission to improve patient outcomes through innovative solutions.

Dr. Kaelin's academic background is equally impressive. He holds a Doctor of Medicine from Duke University School of Medicine, complemented by a Bachelor of Arts in Mathematics and an Associate Bachelor in Chemistry from Duke University. His deep understanding of both the scientific and mathematical aspects of medicine positions him uniquely to guide IQVIA in its ongoing pursuit of excellence in healthcare analytics and research.

IQVIA is recognized as a leading global provider of clinical research services, commercial insights, and healthcare intelligence. The company leverages its advanced capabilities, including AI, analytics, and extensive domain expertise, to deliver actionable insights and services tailored to the life sciences and healthcare industries. With a workforce of approximately 91,000 employees across over 100 countries, IQVIA is committed to accelerating the development and commercialization of innovative medical treatments that enhance patient outcomes and promote population health.

In addition to its focus on innovation, IQVIA prioritizes patient privacy and employs a range of privacy-enhancing technologies to safeguard individual information while conducting extensive healthcare analyses. This dedication to ethical practices further solidifies IQVIA's reputation as a trusted leader in the healthcare sector.

The appointment of Dr. William G. Kaelin Jr. to IQVIA's Board of Directors marks a significant milestone for the company and reflects its ongoing commitment to integrating world-class expertise into its leadership. As IQVIA continues to harness the power of advanced analytics and AI in healthcare, Dr. Kaelin's insights and experience will undoubtedly play a crucial role in shaping the future of clinical research and patient care.